INDIGO’s mission is to provide innovative products and services to reduce time, cost, and risk in the drug discovery process.
How we create value:
- Acting with absolute integrity
- Collaborating, supporting, and respecting one another
- Communicating openly, honestly and frequently
- Developing a highly motivated, valued and diverse workforce
- Optimizing our financial and physical resources
- Simplifying and improving our processes continuously
- Listening to our client’s needs and responding quickly
INDIGO Biosciences, Inc. was founded in 2005 in State College, PA by Dr. Jack Vanden Heuvel and Dr. Blake Peterson. It remains a privately held biosciences company offering products and services focused on nuclear receptors, which comprise a major class of therapeutic drug targets. The founders leveraged their collective expertise in nuclear receptor biology, toxicology, medicinal chemistry, and molecular biology to establish the core platform technology of the Company.
INDIGO Biosciences’ original focus was that of a traditional contract research organization, namely, to provide custom services for the screening of small molecule compounds against functional human and non-human nuclear receptors. Over the years, the Company has demonstrated success in providing quality screening services to clients within the pharmaceutical, biotechnology, food, agriculture, and nutraceutical industries, as well as government research agencies and academic researchers. However, in 2008 the Company’s mission changed dramatically upon the successful development of a unique and superior processing method to cryo-preserve its nuclear receptor reporter cells. This proprietary process, called CryoMite™, provides long-term cryo-preservation of cells for shipping and storage, thus providing users the convenience of readily available robust cell-based reporter assays for on-demand use.